Preliminary study on novel targeted anti-tumor drug aminoglucose based-Doxorubicin

摘要

In order to improve Doxorubicin (Dox) targeting in vivo and reduce toxicity, use the targeting ligand 2-deoxy-aminoglucose (2DG) to modify Doxorubicin to form a new anti-tumor drug. The products was charactered by ~1H-NMR, MS, and the targeting research by near-infrared imaging. Compared with Dox , the product treating MCF-7 and U87MG cells shows higher antitumor activity in vitro by MTT assay. In conclusion, the modified product effectively enhance the targeting and pharmacodynamics in contrast with Dox, and it would be a potential therapeutic drug for cancer.